Seer Biosciences is the next leader in healthcare’s big data revolution – begun with gene expression, continued by genomics, and now, to be completed by proteomics. The rich information presented in the proteome is unrivaled in what it can reveal about the progression of disease, the effectiveness of therapies, and the recovery to health.
Seer’s technology and data will enable patients and their doctors to access these rich insights from the proteome and manage their health in ways not possible today. Our proteomics and data platform allow the identification and validation of novel protein biomarkers that are undetectable with current technology. This data can be used in the development of therapeutics, diagnostics, and healthcare services. The platform works across multiple diseases, and our initial focus is on cancer and serious neurological diseases.
Seer is a privately-held company founded in 2017 by biotechnology veterans Dr. Omid Farokhzad, Dr. Philip Ma, and Dr. Bob Langer. The company is backed by a strong syndicate of investors, including Maverick Ventures, the Invus Group, and select private individuals, family offices, and other institutional investors.
The company is headquartered South San Francisco, California.